Yahoo Finance • 2 days ago
In trading on Wednesday, shares of Worthington Enterprises Inc (Symbol: WOR) entered into oversold territory, changing hands as low as $50.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a te... Full story
Yahoo Finance • 7 days ago
SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrati... Full story
Yahoo Finance • 7 days ago
Key Points Iovance Biotherapeutics' cancer therapy, Amtagvi, is experiencing decent sales growth. However, the biotech faces some challenges that will make it difficult to turn a profit. Though there could be some catalysts on the way, Io... Full story
Yahoo Finance • 9 days ago
NetworkNewsWire Editorial Coverage NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma... Full story
Yahoo Finance • 28 days ago
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story
Yahoo Finance • last month
[financial graph on technology abstract background] monsitj Stock futures edged lower in Tuesday’s premarket trading after a subdued start to a pivotal week marked by key Federal Reserve speeches, major retail earnings, and investor cauti... Full story
Yahoo Finance • last month
[Cancer Outbreak] wildpixel/iStock via Getty Images Iovance Biotherapeutics (NASDAQ:IOVA [https://seekingalpha.com/symbol/IOVA]) shares rose post market after it received Health Canada approval with conditions for its T-cell immunotherapy... Full story
Yahoo Finance • last month
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/q... Full story
Yahoo Finance • last month
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (... Full story
Yahoo Finance • last month
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company with a market capitalization of $890 million specializing in novel cancer immunotherapies, finds itself at a critical juncture as it navigates the complex landscape of on... Full story
Yahoo Finance • last month
Replimune Group Inc (NASDAQ:REPL), a biotechnology company focused on developing novel oncolytic immunotherapies for cancer treatment, has been navigating a complex landscape of clinical trials, regulatory challenges, and market expectatio... Full story
Yahoo Finance • 2 months ago
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT ORIS [https://www.ch... Full story
Yahoo Finance • 2 months ago
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] GAINERS TICKER CHANGE COMMENT MRM [https://www.chartmill.com/stock/quote/MRM/profile] 56.67% ME... Full story
Yahoo Finance • 2 months ago
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07,... Full story
Yahoo Finance • 2 months ago
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company specializing in novel cancer immunotherapies, finds itself at a critical juncture as it navigates the complexities of commercializing its lead product, Amtagvi, while fac... Full story
Yahoo Finance • 2 months ago
Replimune Group Inc (NASDAQ:REPL), a biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, has recently experienced a significant setback in its regulatory journey. Trading at $3.17, the stock has dec... Full story
Yahoo Finance • 2 months ago
It's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story. Some story stocks just don't have enough proven potential... Full story
Yahoo Finance • 2 months ago
Wednesday’s market has seen significant activity, with stocks like Eli Lilly And Co (NYSE:LLY) and GE Vernova LLC (GEV) experiencing notable increases, while Fiserv Inc (NYSE:FI) (FISV) faced a sharp decline. These movements reflect a... Full story
Yahoo Finance • 2 months ago
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, finds itself at a critical juncture. With a market capitalizat... Full story
Yahoo Finance • 2 months ago
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 an... Full story